BioIVT is now a Promega Service Provider offering a range of Promega bioassays to support immunology and immune-oncology research in addition to developing specific assays with client-provided cells and reagents. Our PHASEZERO® Research Services Team has extended their services capabilities to support scientists in screening novel therapeutics by offering a range of robust Promega Bioassays, including measurement of PD-1/PD-L1 blockade activity for out of the box actionable data as well as ability to develop specific data.
The Promega PD-1/PD-L1 Blockade Bioassay, a biologically relevant mechanism of action-based assay, is used to measure the potency and stability of antibodies and other biologicals designed to block the PD-1/PD-L1 interaction. BioIVT’s PHASEZERO® Research Team, with over 20 years of expertise in human-based cell and molecular research, continues to expand our support of immuno-oncology drug development and validation with this and other surrogate reporter bioassay capabilities. These assays allow the measurement of immune checkpoint therapeutic antibody activity, including the following:
- measure potency of monoclonal antibody (mAb) biological drug
- measure potency of unknown biologic to a reference standard
- measure stability (loss of activity due to heat stress)
For more information about our Promega Service Provider Capabilities, please click here (Link to Promega Bioassays home page).